Literature DB >> 18204808

Hypertension risk in idiopathic hyperCKemia.

Lizzy M Brewster1, Sjoerd van Bree, Jaap C Reijneveld, Nicolette C Notermans, W M Monique Verschuren, Joseph F Clark, Gert A van Montfrans, Marianne de Visser.   

Abstract

Patients with idiopathic hyperCKemia are usually reassured and discharged. However, these subjects may have increased hypertension risk, based on data from our population study, which showed that the population tertile with the highest serum creatine kinase activities had the highest systolic and diastolic blood pressure levels. Therefore, we assessed whether subjects with idiopathic hyperCKemia have greater occurrence of hypertension than controls. We included 46 participants aged 18 to 67 years, diagnosed with idiopathic hyperCKemia at the departments of Neurology of the Universities of Amsterdam and Utrecht, The Netherlands. We found that 48% of the subjects with idiopathic hyperCKemia were hypertensive, as compared to 19% of the random population controls (n = 22,612, aged 20 to 65 years), an odds ratio of 3.9 (95 % CI, 2.2 to 6.9) before, and 2.0 (1.1 to 3.8) after adjustment for sex, age, and body mass index. In accord with our previous finding of an association between creatine kinase and blood pressure in the general population, the data reported here suggest that subjects with idiopathic hyperCKemia have greater hypertension risk than controls. This may be due to relatively high tissue creatine kinase activity, resulting in greater ATP buffer capacity to create and sustain high blood pressure levels.Larger, prospective studies are needed to further assess this association, but as active case finding is important in the diagnosis of hypertension, subjects with idiopathic hyperCKemia should be screened and monitored for the presence of hypertension.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18204808     DOI: 10.1007/s00415-008-0651-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  24 in total

1.  IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 degrees C. Part 2. Reference procedure for the measurement of catalytic concentration of creatine kinase.

Authors:  Gerhard Schumann; Roberto Bonora; Ferruccio Ceriotti; Pascale Clerc-Renaud; Carlo A Ferrero; Georges Férard; Paul F H Franck; F Javier Gella; Wieland Hoelzel; Poul Jørgen Jørgensen; Takashi Kanno; Art Kessne; Rainer Klauker; Nina Kristiansen; Jean-Marc Lessinger; Thomas P J Linsinger; Hideo Misaki; Mauro Panteghini; Jean Pauwels; Heinz G Schimmel; Arlette Vialle; Gerhard Weidemann; Lothar Siekmann
Journal:  Clin Chem Lab Med       Date:  2002-06       Impact factor: 3.694

2.  Muscle fiber-type distribution as a predictor of blood pressure: a 19-year follow-up study.

Authors:  Miika Hernelahti; Heikki O Tikkanen; Jouko Karjalainen; Urho M Kujala
Journal:  Hypertension       Date:  2005-04-18       Impact factor: 10.190

3.  Epidemiology of neurological diseases in elderly people: what did we learn from the Rotterdam Study?

Authors:  Albert Hofman; Paulus T V M de Jong; Cornelia M van Duijn; Monique M B Breteler
Journal:  Lancet Neurol       Date:  2006-06       Impact factor: 44.182

Review 4.  The creatine kinase system in smooth muscle.

Authors:  J F Clark
Journal:  Mol Cell Biochem       Date:  1994 Apr-May       Impact factor: 3.396

5.  Creatine kinase as an intracellular regulator.

Authors:  M R Iyengar
Journal:  J Muscle Res Cell Motil       Date:  1984-10       Impact factor: 2.698

6.  Persistent hyperCKemia: fourteen patients studied in retrospect.

Authors:  L M Brewster; M de Visser
Journal:  Acta Neurol Scand       Date:  1988-01       Impact factor: 3.209

Review 7.  Is greater tissue activity of creatine kinase the genetic factor increasing hypertension risk in black people of sub-Saharan African descent?

Authors:  L M Brewster; J F Clark; G A van Montfrans
Journal:  J Hypertens       Date:  2000-11       Impact factor: 4.844

8.  Liver damage as a potential source of error in the estimation of myocardial infarct size from plasma creatine kinase activity.

Authors:  R J Oostenbroek; G M Willems; M L Boumans; P B Soeters; W T Hermens
Journal:  Cardiovasc Res       Date:  1985-02       Impact factor: 10.787

Review 9.  Arginine metabolism: nitric oxide and beyond.

Authors:  G Wu; S M Morris
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

10.  Skeletal muscle creatine kinase MB alterations in women marathon runners.

Authors:  F S Apple; M A Rogers; D C Casal; L Lewis; J L Ivy; J W Lampe
Journal:  Eur J Appl Physiol Occup Physiol       Date:  1987
View more
  7 in total

Review 1.  Creatine kinase, energy reserve, and hypertension: from bench to bedside.

Authors:  Lizzy M Brewster
Journal:  Ann Transl Med       Date:  2018-08

Review 2.  Extracellular creatine kinase may modulate purinergic signalling.

Authors:  L M Brewster
Journal:  Purinergic Signal       Date:  2020-06-23       Impact factor: 3.765

3.  Creatinine kinase and hypertension.

Authors:  Lizzy M Brewster; Gert A van Montfrans
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-06       Impact factor: 3.738

4.  Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR.

Authors:  Wolter L de Graaf; Jaco J M Zwanenburg; Fredy Visser; Mike P Wattjes; Petra J W Pouwels; Jeroen J G Geurts; Chris H Polman; Frederik Barkhof; Peter R Luijten; Jonas A Castelijns
Journal:  Eur Radiol       Date:  2011-08-27       Impact factor: 5.315

5.  The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC Trial): study protocol for a randomized controlled trial.

Authors:  Fares A Karamat; Deborah L Horjus; Yentl C Haan; Lisa van der Woude; Inge Oudman; Gert A van Montfrans; Joseph F Clark; Lizzy M Brewster
Journal:  Trials       Date:  2015-02-22       Impact factor: 2.279

6.  The acute effect of beta-guanidinopropionic acid versus creatine or placebo in healthy men (ABC-Trial): A randomized controlled first-in-human trial.

Authors:  Fares A Karamat; Deborah L Horjus; Yentl C Haan; Lisa van der Woude; Marianne C Schaap; Inge Oudman; Gert A van Montfrans; Rienk Nieuwland; Gajja S Salomons; Joseph F Clark; Lizzy M Brewster
Journal:  Br J Clin Pharmacol       Date:  2017-09-20       Impact factor: 4.335

7.  Cardiovascular function is not associated with creatine kinase activity in a black African population: The SABPA study.

Authors:  Catharina M C Mels; Caitlynd van Zyl; Hugo W Huisman
Journal:  BMC Cardiovasc Disord       Date:  2016-06-10       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.